JP2016519684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519684A5 JP2016519684A5 JP2016507620A JP2016507620A JP2016519684A5 JP 2016519684 A5 JP2016519684 A5 JP 2016519684A5 JP 2016507620 A JP2016507620 A JP 2016507620A JP 2016507620 A JP2016507620 A JP 2016507620A JP 2016519684 A5 JP2016519684 A5 JP 2016519684A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- combination
- agent
- kinase
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 95
- 239000003112 inhibitor Substances 0.000 claims 78
- 239000000203 mixture Substances 0.000 claims 61
- 229940124597 therapeutic agent Drugs 0.000 claims 41
- 230000000694 effects Effects 0.000 claims 39
- 229940079593 drug Drugs 0.000 claims 38
- 230000006872 improvement Effects 0.000 claims 34
- 229940100198 alkylating agent Drugs 0.000 claims 32
- 239000002168 alkylating agent Substances 0.000 claims 32
- 229940002612 prodrug Drugs 0.000 claims 27
- 239000000651 prodrug Substances 0.000 claims 27
- 241000219198 Brassica Species 0.000 claims 24
- 235000003351 Brassica cretica Nutrition 0.000 claims 24
- 235000003343 Brassica rupestris Nutrition 0.000 claims 24
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 24
- 235000010460 mustard Nutrition 0.000 claims 24
- 238000002651 drug therapy Methods 0.000 claims 23
- 238000000034 method Methods 0.000 claims 23
- 239000003795 chemical substances by application Substances 0.000 claims 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 18
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 18
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 16
- 238000009472 formulation Methods 0.000 claims 16
- 230000014509 gene expression Effects 0.000 claims 15
- 108060006633 protein kinase Proteins 0.000 claims 15
- 230000001225 therapeutic effect Effects 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 238000002360 preparation method Methods 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 102000001253 Protein Kinase Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1h-pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 claims 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical group NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical group ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims 10
- 239000002775 capsule Substances 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 10
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 9
- 229960001948 caffeine Drugs 0.000 claims 9
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims 8
- 229960001338 colchicine Drugs 0.000 claims 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 8
- 239000002552 dosage form Substances 0.000 claims 8
- 238000012377 drug delivery Methods 0.000 claims 8
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 8
- 229960001055 uracil mustard Drugs 0.000 claims 8
- 102000004190 Enzymes Human genes 0.000 claims 7
- 108090000790 Enzymes Proteins 0.000 claims 7
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 7
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 7
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 7
- 230000003993 interaction Effects 0.000 claims 7
- 238000007726 management method Methods 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 230000019491 signal transduction Effects 0.000 claims 7
- 238000013268 sustained release Methods 0.000 claims 7
- 239000012730 sustained-release form Substances 0.000 claims 7
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims 6
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims 6
- 102000008186 Collagen Human genes 0.000 claims 6
- 108010035532 Collagen Proteins 0.000 claims 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 6
- 108010022394 Threonine synthase Proteins 0.000 claims 6
- 238000004458 analytical method Methods 0.000 claims 6
- 239000002111 antiemetic agent Substances 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims 6
- 229940093265 berberine Drugs 0.000 claims 6
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 6
- 229920001436 collagen Polymers 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 6
- 229960002411 imatinib Drugs 0.000 claims 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 6
- 229960003966 nicotinamide Drugs 0.000 claims 6
- 235000005152 nicotinamide Nutrition 0.000 claims 6
- 239000011570 nicotinamide Substances 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- DFWRZHZPJJAJMX-UHFFFAOYSA-N propanimidamide;hydrochloride Chemical compound Cl.CCC(N)=N DFWRZHZPJJAJMX-UHFFFAOYSA-N 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 6
- 108091000080 Phosphotransferase Proteins 0.000 claims 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 230000003474 anti-emetic effect Effects 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 5
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 102000020233 phosphotransferase Human genes 0.000 claims 5
- 230000001988 toxicity Effects 0.000 claims 5
- 231100000419 toxicity Toxicity 0.000 claims 5
- QNOCRUSVMMAKSC-CCEZHUSRSA-N (3e)-1-methyl-3-(2-oxo-1h-indol-3-ylidene)indol-2-one Chemical compound C12=CC=CC=C2N(C)C(=O)\C1=C\1C2=CC=CC=C2NC/1=O QNOCRUSVMMAKSC-CCEZHUSRSA-N 0.000 claims 4
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 4
- 229920000858 Cyclodextrin Polymers 0.000 claims 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 108090000353 Histone deacetylase Proteins 0.000 claims 4
- 101000634975 Homo sapiens Tripartite motif-containing protein 29 Proteins 0.000 claims 4
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 4
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims 4
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims 4
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims 4
- 206010070834 Sensitisation Diseases 0.000 claims 4
- 102000005497 Thymidylate Synthase Human genes 0.000 claims 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 4
- 229940122803 Vinca alkaloid Drugs 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000000340 anti-metabolite Effects 0.000 claims 4
- 229940100197 antimetabolite Drugs 0.000 claims 4
- 239000002256 antimetabolite Substances 0.000 claims 4
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims 4
- 235000008714 apigenin Nutrition 0.000 claims 4
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims 4
- 229940117893 apigenin Drugs 0.000 claims 4
- 229960002707 bendamustine Drugs 0.000 claims 4
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 4
- 238000001815 biotherapy Methods 0.000 claims 4
- 229940127093 camptothecin Drugs 0.000 claims 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 4
- 230000008859 change Effects 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- 229940109262 curcumin Drugs 0.000 claims 4
- 235000012754 curcumin Nutrition 0.000 claims 4
- 239000004148 curcumin Substances 0.000 claims 4
- 229960000684 cytarabine Drugs 0.000 claims 4
- 229960002448 dasatinib Drugs 0.000 claims 4
- 239000008121 dextrose Substances 0.000 claims 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 4
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 4
- 229960005420 etoposide Drugs 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- 229940045109 genistein Drugs 0.000 claims 4
- 235000006539 genistein Nutrition 0.000 claims 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- AXESYCSCGBQJBL-SZPBEECKSA-N largazole Chemical compound O=C([C@@]1(C)N=C2SC1)N[C@@H](C(C)C)C(=O)O[C@H](/C=C/CCSC(=O)CCCCCCC)CC(=O)NCC1=NC2=CS1 AXESYCSCGBQJBL-SZPBEECKSA-N 0.000 claims 4
- 239000012931 lyophilized formulation Substances 0.000 claims 4
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims 4
- 230000036457 multidrug resistance Effects 0.000 claims 4
- 229960001346 nilotinib Drugs 0.000 claims 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 238000004806 packaging method and process Methods 0.000 claims 4
- 239000000816 peptidomimetic Substances 0.000 claims 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 4
- 150000003057 platinum Chemical class 0.000 claims 4
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 4
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 4
- 238000002203 pretreatment Methods 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims 4
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 4
- 230000008313 sensitization Effects 0.000 claims 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 239000008215 water for injection Substances 0.000 claims 4
- 230000003442 weekly effect Effects 0.000 claims 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 229940124291 BTK inhibitor Drugs 0.000 claims 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 3
- 229940125683 antiemetic agent Drugs 0.000 claims 3
- 230000021615 conjugation Effects 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 230000010534 mechanism of action Effects 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 229960003581 pyridoxal Drugs 0.000 claims 3
- 235000008164 pyridoxal Nutrition 0.000 claims 3
- 239000011674 pyridoxal Substances 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 230000008439 repair process Effects 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- -1 β-D-ribofuranuronic acid ethyl ester Chemical compound 0.000 claims 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical compound C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 claims 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 claims 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 2
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 claims 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 claims 2
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 claims 2
- CYAAFLGWAUCWEF-UHFFFAOYSA-N 5-nitro-1-(4-nitrophenyl)pyrimidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C(=O)NC(=O)C([N+]([O-])=O)=C1 CYAAFLGWAUCWEF-UHFFFAOYSA-N 0.000 claims 2
- PKUFNWPSFCOSLU-UHFFFAOYSA-N 6-chloro-1h-pyrimidine-2,4-dione Chemical compound ClC1=CC(=O)NC(=O)N1 PKUFNWPSFCOSLU-UHFFFAOYSA-N 0.000 claims 2
- JKUXMZDHLUUPGG-UHFFFAOYSA-N 6-ethyl-1h-pyrimidine-2,4-dione Chemical compound CCC1=CC(=O)NC(=O)N1 JKUXMZDHLUUPGG-UHFFFAOYSA-N 0.000 claims 2
- SHVCSCWHWMSGTE-UHFFFAOYSA-N 6-methyluracil Chemical compound CC1=CC(=O)NC(=O)N1 SHVCSCWHWMSGTE-UHFFFAOYSA-N 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 claims 2
- 102000006772 Acid Ceramidase Human genes 0.000 claims 2
- 108020005296 Acid Ceramidase Proteins 0.000 claims 2
- 229940123786 Adenosine A3 receptor antagonist Drugs 0.000 claims 2
- 229940122098 Angiopoietin-like 4 protein inhibitor Drugs 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 108091007065 BIRCs Proteins 0.000 claims 2
- 101000796998 Bacillus subtilis (strain 168) Methylated-DNA-protein-cysteine methyltransferase, inducible Proteins 0.000 claims 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 102000052052 Casein Kinase II Human genes 0.000 claims 2
- 108010010919 Casein Kinase II Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 229940121737 Choline kinase inhibitor Drugs 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims 2
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims 2
- 101710095468 Cyclase Proteins 0.000 claims 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims 2
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 2
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102000005720 Glutathione transferase Human genes 0.000 claims 2
- 108010070675 Glutathione transferase Proteins 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 2
- 101710184069 Hepatocyte growth factor receptor Proteins 0.000 claims 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 claims 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 102000042838 JAK family Human genes 0.000 claims 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 claims 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 claims 2
- 102000002151 Microfilament Proteins Human genes 0.000 claims 2
- 108010040897 Microfilament Proteins Proteins 0.000 claims 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 2
- 235000021360 Myristic acid Nutrition 0.000 claims 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 2
- 101150056950 Ntrk2 gene Proteins 0.000 claims 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 2
- 108010038807 Oligopeptides Proteins 0.000 claims 2
- 102000015636 Oligopeptides Human genes 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 239000012661 PARP inhibitor Substances 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 claims 2
- 108091008611 Protein Kinase B Proteins 0.000 claims 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims 2
- 102000013009 Pyruvate Kinase Human genes 0.000 claims 2
- 108020005115 Pyruvate Kinase Proteins 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 229940123690 Raf kinase inhibitor Drugs 0.000 claims 2
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 claims 2
- 108091005682 Receptor kinases Proteins 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 108010083644 Ribonucleases Proteins 0.000 claims 2
- 102000006382 Ribonucleases Human genes 0.000 claims 2
- 101150099493 STAT3 gene Proteins 0.000 claims 2
- 239000002262 Schiff base Substances 0.000 claims 2
- 150000004753 Schiff bases Chemical class 0.000 claims 2
- 102100020824 Serine-protein kinase ATM Human genes 0.000 claims 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 2
- 241000700584 Simplexvirus Species 0.000 claims 2
- 241000710960 Sindbis virus Species 0.000 claims 2
- 229940122171 Sphingomyelinase inhibitor Drugs 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 108010017842 Telomerase Proteins 0.000 claims 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 2
- 229940122954 Transcription factor inhibitor Drugs 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 102100029519 Tripartite motif-containing protein 29 Human genes 0.000 claims 2
- 108010092464 Urate Oxidase Proteins 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 2
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 239000002580 adenosine A3 receptor antagonist Substances 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 2
- 229960003459 allopurinol Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 229960005475 antiinfective agent Drugs 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 239000002221 antipyretic Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 239000005441 aurora Substances 0.000 claims 2
- 229960001215 bendamustine hydrochloride Drugs 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 108091008324 binding proteins Proteins 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 238000010322 bone marrow transplantation Methods 0.000 claims 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims 2
- 229940022399 cancer vaccine Drugs 0.000 claims 2
- 238000009566 cancer vaccine Methods 0.000 claims 2
- 229930003827 cannabinoid Natural products 0.000 claims 2
- 239000003557 cannabinoid Substances 0.000 claims 2
- 229940065144 cannabinoids Drugs 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims 2
- 229960001380 cimetidine Drugs 0.000 claims 2
- 230000003081 coactivator Effects 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 239000003431 cross linking reagent Substances 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
- 150000001944 cysteine derivatives Chemical class 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 229940124447 delivery agent Drugs 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 238000012631 diagnostic technique Methods 0.000 claims 2
- 102000004419 dihydrofolate reductase Human genes 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 238000006471 dimerization reaction Methods 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 229940030606 diuretics Drugs 0.000 claims 2
- 230000003828 downregulation Effects 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 230000001973 epigenetic effect Effects 0.000 claims 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 229960000556 fingolimod Drugs 0.000 claims 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960005102 foscarnet Drugs 0.000 claims 2
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 229910001385 heavy metal Inorganic materials 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 229960001330 hydroxycarbamide Drugs 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 108010039490 largazole Proteins 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- YDDMIZRDDREKEP-HWTBNCOESA-N lurbinectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1NC1=CC=C(C=C13)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 YDDMIZRDDREKEP-HWTBNCOESA-N 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 150000002678 macrocyclic compounds Chemical class 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims 2
- 239000000693 micelle Substances 0.000 claims 2
- 239000004005 microsphere Substances 0.000 claims 2
- 230000003278 mimic effect Effects 0.000 claims 2
- 229960003539 mitoguazone Drugs 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 238000003032 molecular docking Methods 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- JKMILVOVUWCVPG-UHFFFAOYSA-N n',n'-bis(2-chloroethyl)ethane-1,2-diamine Chemical compound NCCN(CCCl)CCCl JKMILVOVUWCVPG-UHFFFAOYSA-N 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 239000002159 nanocrystal Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims 2
- 108020004017 nuclear receptors Proteins 0.000 claims 2
- 230000025308 nuclear transport Effects 0.000 claims 2
- 229960003347 obinutuzumab Drugs 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 claims 2
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960005184 panobinostat Drugs 0.000 claims 2
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 claims 2
- 238000002823 phage display Methods 0.000 claims 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 2
- 229960003243 phenformin Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 claims 2
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- RJXQSIKBGKVNRT-UHFFFAOYSA-N phosphoramide mustard Chemical compound ClCCN(P(O)(=O)N)CCCl RJXQSIKBGKVNRT-UHFFFAOYSA-N 0.000 claims 2
- 150000008299 phosphorodiamidates Chemical class 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 2
- 239000003909 protein kinase inhibitor Substances 0.000 claims 2
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 2
- 239000013557 residual solvent Substances 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 239000003590 rho kinase inhibitor Substances 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 238000009118 salvage therapy Methods 0.000 claims 2
- 239000002002 slurry Substances 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 239000002732 sphingomyelin phosphodiesterase inhibitor Substances 0.000 claims 2
- 229950006315 spirogermanium Drugs 0.000 claims 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 2
- 231100000617 superantigen Toxicity 0.000 claims 2
- 239000000829 suppository Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 2
- 229940100611 topical cream Drugs 0.000 claims 2
- 229940042129 topical gel Drugs 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 239000013638 trimer Substances 0.000 claims 2
- 229940035893 uracil Drugs 0.000 claims 2
- 229940116269 uric acid Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 2
- 229960000237 vorinostat Drugs 0.000 claims 2
- 229930007631 (-)-perillyl alcohol Natural products 0.000 claims 1
- ZYFONFJPXBIBLI-KBMWBBLPSA-N (4r)-4-[(8r,9s,10s,13r,14s,17r)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanamide Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(N)=O)C)[C@@]1(C)CC2 ZYFONFJPXBIBLI-KBMWBBLPSA-N 0.000 claims 1
- ZIMFQFMUIGMSEQ-UHFFFAOYSA-N 1-hydroxy-5-nitropyrimidine-2,4-dione Chemical compound On1cc([N+]([O-])=O)c(=O)[nH]c1=O ZIMFQFMUIGMSEQ-UHFFFAOYSA-N 0.000 claims 1
- ZTGWXXOUUKHQLW-UHFFFAOYSA-N 1-nitropyrimidine-2,4-dione Chemical compound [O-][N+](=O)N1C=CC(=O)NC1=O ZTGWXXOUUKHQLW-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- HZSKRKPZUQECIE-UHFFFAOYSA-N 2-ethoxy-n-[4-[(5-methyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]acetamide Chemical class C1=CC(NC(=O)COCC)=CC=C1S(=O)(=O)NC1=NOC(C)=C1 HZSKRKPZUQECIE-UHFFFAOYSA-N 0.000 claims 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 claims 1
- PMHOWXRNJXWYIP-UHFFFAOYSA-N 4,5-dihydrooxazaphosphole Chemical class C1CP=NO1 PMHOWXRNJXWYIP-UHFFFAOYSA-N 0.000 claims 1
- BXOUFHBYBVNPPU-UHFFFAOYSA-N 5-[bis(2-chloroethyl)aminomethyl]-1,3-dimethylpyrimidine-2,4-dione Chemical compound CN1C=C(CN(CCCl)CCCl)C(=O)N(C)C1=O BXOUFHBYBVNPPU-UHFFFAOYSA-N 0.000 claims 1
- AVQSJLFYXJNZHI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)aminomethyl]-1-methylpyrimidine-2,4-dione Chemical compound CN1C=C(CN(CCCl)CCCl)C(=O)NC1=O AVQSJLFYXJNZHI-UHFFFAOYSA-N 0.000 claims 1
- DSNDKLPCPVXPMQ-UHFFFAOYSA-N 5-[bis(2-chloroethyl)aminomethyl]-1h-pyrimidine-2,4-dione Chemical compound ClCCN(CCCl)CC1=CNC(=O)NC1=O DSNDKLPCPVXPMQ-UHFFFAOYSA-N 0.000 claims 1
- QLCSQGFYPNEMBN-UHFFFAOYSA-N 5-[bis(2-chloroethyl)aminomethyl]-6-methyl-1h-pyrimidine-2,4-dione Chemical compound CC=1NC(=O)NC(=O)C=1CN(CCCl)CCCl QLCSQGFYPNEMBN-UHFFFAOYSA-N 0.000 claims 1
- AZXCUOMVEXRBFD-UHFFFAOYSA-N 5-[bis(2-chloroethyl)aminomethyl]-6-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC=1NC(=S)NC(=O)C=1CN(CCCl)CCCl AZXCUOMVEXRBFD-UHFFFAOYSA-N 0.000 claims 1
- XVEFFLYRDVITRB-UHFFFAOYSA-N 5-[bis(2-chloroethyl)aminomethyl]-6-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCC=1NC(=O)NC(=O)C=1CN(CCCl)CCCl XVEFFLYRDVITRB-UHFFFAOYSA-N 0.000 claims 1
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical class NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 claims 1
- NVKJOXRVEKMMHS-UHFFFAOYSA-N 5-nitro-1,2,4-triazol-3-one Chemical compound [O-][N+](=O)C1=NC(=O)N=N1 NVKJOXRVEKMMHS-UHFFFAOYSA-N 0.000 claims 1
- JWNSFESVPQPBGS-UHFFFAOYSA-N 5-nitro-1,3-diazinane-2,4-dione Chemical compound [O-][N+](=O)C1CNC(=O)NC1=O JWNSFESVPQPBGS-UHFFFAOYSA-N 0.000 claims 1
- BUMUBHQTPIIMCO-UHFFFAOYSA-N 5-nitro-1-(4-nitrophenyl)-1,3-diazinane-2,4-dione Chemical compound O=C1NC(=O)C([N+](=O)[O-])CN1C1=CC=C([N+]([O-])=O)C=C1 BUMUBHQTPIIMCO-UHFFFAOYSA-N 0.000 claims 1
- IMUTYIOWQFQGIC-UHFFFAOYSA-N 6-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCC1=CC(=O)NC(=O)N1 IMUTYIOWQFQGIC-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 229940125775 ATR kinase inhibitor Drugs 0.000 claims 1
- 102100027211 Albumin Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010059313 Anogenital warts Diseases 0.000 claims 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000004860 Blast Crisis Diseases 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 1
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 230000007118 DNA alkylation Effects 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 108010032035 Desmoglein 3 Proteins 0.000 claims 1
- 102000007577 Desmoglein 3 Human genes 0.000 claims 1
- 229940122601 Esterase inhibitor Drugs 0.000 claims 1
- 108010029961 Filgrastim Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 1
- 102100023915 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 108010049358 Oncogene Protein p65(gag-jun) Proteins 0.000 claims 1
- 208000004179 Oral Leukoplakia Diseases 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 108090000315 Protein Kinase C Proteins 0.000 claims 1
- 102000003923 Protein Kinase C Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 102000014384 Type C Phospholipases Human genes 0.000 claims 1
- 108010079194 Type C Phospholipases Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000001142 anti-diarrhea Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 229940125716 antipyretic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000002725 brachytherapy Methods 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000002329 esterase inhibitor Substances 0.000 claims 1
- 229960001842 estramustine Drugs 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 238000010195 expression analysis Methods 0.000 claims 1
- 229930003944 flavone Natural products 0.000 claims 1
- 150000002213 flavones Chemical class 0.000 claims 1
- 235000011949 flavones Nutrition 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 229960004783 fotemustine Drugs 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims 1
- 150000002515 isoflavone derivatives Chemical class 0.000 claims 1
- 235000008696 isoflavones Nutrition 0.000 claims 1
- 229960003350 isoniazid Drugs 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 229960002247 lomustine Drugs 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 229950008612 mannomustine Drugs 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229940029345 neupogen Drugs 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 229960001420 nimustine Drugs 0.000 claims 1
- 231100000957 no side effect Toxicity 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 201000008557 oral mucosa leukoplakia Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 235000005693 perillyl alcohol Nutrition 0.000 claims 1
- 230000003285 pharmacodynamic effect Effects 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000003504 photosensitizing agent Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 229960004694 prednimustine Drugs 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 150000003223 pyridoxals Chemical class 0.000 claims 1
- UKOBAUFLOGFCMV-UHFFFAOYSA-N quinacrine mustard Chemical compound C1=C(Cl)C=CC2=C(NC(C)CCCN(CCCl)CCCl)C3=CC(OC)=CC=C3N=C21 UKOBAUFLOGFCMV-UHFFFAOYSA-N 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 229960002185 ranimustine Drugs 0.000 claims 1
- 108091006084 receptor activators Proteins 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 102000034285 signal transducing proteins Human genes 0.000 claims 1
- 108091006024 signal transducing proteins Proteins 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229950006050 spiromustine Drugs 0.000 claims 1
- 238000009168 stem cell therapy Methods 0.000 claims 1
- 238000009580 stem-cell therapy Methods 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000009452 underexpressoin Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000004066 vascular targeting agent Substances 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809627P | 2013-04-08 | 2013-04-08 | |
| US61/809,627 | 2013-04-08 | ||
| PCT/US2014/033391 WO2014168986A1 (en) | 2013-04-08 | 2014-04-08 | Therapeutic benefit of suboptimally administered chemical compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019099028A Division JP2019135268A (ja) | 2013-04-08 | 2019-05-28 | 準最適に投与された化学化合物の治療的有効性 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016519684A JP2016519684A (ja) | 2016-07-07 |
| JP2016519684A5 true JP2016519684A5 (enExample) | 2017-05-25 |
Family
ID=51689967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507620A Pending JP2016519684A (ja) | 2013-04-08 | 2014-04-08 | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| JP2019099028A Pending JP2019135268A (ja) | 2013-04-08 | 2019-05-28 | 準最適に投与された化学化合物の治療的有効性 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019099028A Pending JP2019135268A (ja) | 2013-04-08 | 2019-05-28 | 準最適に投与された化学化合物の治療的有効性 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11491154B2 (enExample) |
| EP (1) | EP2983674A4 (enExample) |
| JP (2) | JP2016519684A (enExample) |
| KR (1) | KR20160061911A (enExample) |
| CN (1) | CN105492011A (enExample) |
| AU (4) | AU2014251038A1 (enExample) |
| WO (1) | WO2014168986A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| WO2014179528A2 (en) * | 2013-05-01 | 2014-11-06 | Brown Dennis M | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
| HUE066123T2 (hu) | 2013-06-13 | 2024-07-28 | Akebia Therapeutics Inc | Készítmények és módszerek anémia kezelésére |
| CN105764491A (zh) | 2013-12-09 | 2016-07-13 | 度瑞公司 | 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法 |
| CA2974691A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| MX374909B (es) * | 2015-04-01 | 2025-03-06 | Akebia Therapeutics Inc | El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia. |
| EP3118621A1 (en) * | 2015-07-14 | 2017-01-18 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
| US20190224325A1 (en) | 2016-06-29 | 2019-07-25 | Therabiopharma Inc. | Drug composition for parenteral administration |
| US10449269B2 (en) * | 2016-08-29 | 2019-10-22 | Yale University | Particle conjugated prosthetic patches and methods of making and using thereof |
| MX2019011496A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| KR20200052349A (ko) | 2017-09-11 | 2020-05-14 | 아토사 테라퓨틱스, 인크. | 엔독시펜을 제조 및 사용하는 방법 |
| BR112020006039A2 (pt) * | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| EP3773502A4 (en) * | 2018-04-06 | 2022-05-18 | UCAR Health GmbH | TREATMENT OF CANCER BY GUANIDINIUM DERIVATIVES |
| IL278533B1 (en) | 2018-05-09 | 2025-10-01 | Akebia Therapeutics Inc | Process for the preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| CN108754160B (zh) * | 2018-07-26 | 2020-05-08 | 江苏理工学院 | 一种吡哆醛含锰废水的回收利用方法 |
| EP3616725A1 (en) * | 2018-08-27 | 2020-03-04 | SmartDyeLivery GmbH | Pkc inhibitors for the treatment of septic cholestasis with polymethine dye targeting |
| CN109628570A (zh) * | 2018-12-07 | 2019-04-16 | 南方医科大学南方医院 | 一种检测TRIM29基因Tyr544Cys突变的试剂盒及其用途 |
| CN109394692B (zh) * | 2018-12-12 | 2020-09-25 | 中国药科大学 | 达沙替尼接枝型聚合物胶束、其冻干粉针剂及制备方法和应用 |
| JP7157263B2 (ja) | 2019-07-01 | 2022-10-19 | オークウッド ラボラトリーズ，エル．エル．シー． | ミクロスフェア及びエマルションを製造するためのシステム及び方法 |
| US12201591B2 (en) | 2019-07-03 | 2025-01-21 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
| CN110491443B (zh) * | 2019-07-23 | 2022-04-01 | 华中师范大学 | 一种基于投影邻域非负矩阵分解的lncRNA蛋白质关联预测方法 |
| MA57563A1 (fr) * | 2020-01-30 | 2022-10-31 | Purcann Pharma Inc | Procédé de prévention ou de réduction de la décomposition de la biomasse de cannabaceae |
| CN113045550A (zh) * | 2021-03-12 | 2021-06-29 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
| CN117794544A (zh) * | 2021-09-08 | 2024-03-29 | 卫材R&D管理有限公司 | 实体瘤治疗用医药组合物 |
| CN113929081B (zh) * | 2021-10-13 | 2023-04-14 | 西南大学 | 上下转换双发射全色光谱碳点及其合成方法和应用 |
| CN114425054A (zh) * | 2022-01-20 | 2022-05-03 | 中国人民解放军军事科学院军事医学研究院 | 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途 |
| CN117205225B (zh) * | 2023-09-12 | 2024-05-31 | 湖南普瑞玛药物研究中心有限公司 | 栀子苷在制备治疗骨髓增殖性肿瘤药物中的应用 |
| CN117860948B (zh) * | 2024-03-12 | 2024-06-04 | 江西永通科技股份有限公司 | 一种医用复合功能型抗菌敷料及其制备方法 |
Family Cites Families (236)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2969364A (en) | 1957-12-26 | 1961-01-24 | Upjohn Co | Derivatives of 5-amino uracil |
| US3008491A (en) | 1959-05-04 | 1961-11-14 | Chapman Valve Mfg Co | Valve for concentric pipe lines |
| US3012976A (en) | 1959-11-02 | 1961-12-12 | Miles Lab | Specific test composition for occult blood |
| US3008281A (en) | 1960-07-14 | 1961-11-14 | Nat Dairy Prod Corp | Conveyor |
| US3299104A (en) | 1963-04-09 | 1967-01-17 | Leo Ab | Certain steroid nu-bis-(haloethyl)-carbamates |
| JPS59186924A (ja) | 1983-04-08 | 1984-10-23 | Kureha Chem Ind Co Ltd | ヒト免疫グロブリン結合抗腫瘍剤 |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5035878A (en) | 1988-09-12 | 1991-07-30 | University Of Rochester | Use of dithiocarbamates to counteract myelosuppression |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| US5484612A (en) | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
| US6011069A (en) | 1995-12-26 | 2000-01-04 | Nisshin Flour Milling Co., Ltd. | Multidrug resistance inhibitors |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| ES2263178T3 (es) | 1996-06-27 | 2006-12-01 | Chugai Seiyaku Kabushiki Kaisha | Remedios para mieloma para ser utilizados junto con agentes antitumorales de mostaza nitrogenada. |
| US6121245A (en) | 1997-01-29 | 2000-09-19 | Firshein; Richard N. | Method of treating cancer using alkylglycerols in conjunction with chemotherapy |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US20040072889A1 (en) | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| EP1019034A2 (en) | 1997-07-01 | 2000-07-19 | Atherogenics, Inc. | Antioxidant enhancement of therapy for hyperproliferative conditions |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| CA2329130A1 (en) | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
| AU4543899A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| KR20000011247A (ko) * | 1998-07-23 | 2000-02-25 | 김윤 | 다당류를이용한대장선택성약물전달조성물및약학제제 |
| EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
| US6326390B1 (en) | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
| EP1165085B1 (en) | 1999-03-30 | 2006-06-14 | Novartis AG | Phthalazine derivatives for treating inflammatory diseases |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| US8791081B2 (en) | 1999-08-13 | 2014-07-29 | Case Western Reserve University | MGMT inhibitor combination for the treatment of neoplastic disorders |
| US7811981B2 (en) | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| ATE465756T1 (de) | 2000-06-23 | 2010-05-15 | Mitsubishi Tanabe Pharma Corp | Antitumoreffekt-verstärker |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
| ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| US7619005B2 (en) | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
| US20100098691A1 (en) | 2001-01-24 | 2010-04-22 | S'bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| IL159048A0 (en) | 2001-06-21 | 2004-05-12 | Genentech Inc | Sustained release formulation |
| US20030158118A1 (en) | 2001-11-26 | 2003-08-21 | Weidner Morten Sloth | Combination of cimetidine and cysteine derivatives for treating cancer |
| US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| EP2138575B8 (en) | 2002-02-20 | 2013-07-24 | Mersana Therapeutics, Inc. | Conjugates comprising a biodegradable polymer and uses therefor |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| DE60332762D1 (de) | 2002-11-12 | 2010-07-08 | Jewish General Hospital Montre | Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie |
| ATE449081T1 (de) | 2002-12-30 | 2009-12-15 | Celgene Corp | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen |
| DK1603570T5 (da) | 2003-02-26 | 2013-12-09 | Sugen Inc | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
| US20070207952A1 (en) | 2003-03-24 | 2007-09-06 | Sequoia Pharmaceuticals | Long Acting Biologically Active Conjugates |
| CA2520586C (en) | 2003-03-27 | 2011-06-14 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| WO2004103958A2 (en) | 2003-05-19 | 2004-12-02 | Michigan State University | Preparation of hymenialdisine derivatives and use thereof |
| US7842835B2 (en) | 2003-07-07 | 2010-11-30 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| ES2317047T3 (es) | 2003-08-07 | 2009-04-16 | Schering Corporation | Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales. |
| AU2004270187A1 (en) | 2003-09-04 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) |
| HUP0303313A2 (hu) | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transzdermális gyógyszerkészítmények |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| US8435539B2 (en) | 2004-02-13 | 2013-05-07 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| WO2005092326A1 (en) | 2004-03-22 | 2005-10-06 | The Regents Of The University Of Michigan | Small molecule antagonists of xiap family proteins |
| JP4993374B2 (ja) | 2004-04-05 | 2012-08-08 | メルク エイチディーエーシー リサーチ エルエルシー | ヒストン脱アセチル化酵素インヒビタープロドラッグ |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| TW200600091A (en) | 2004-05-21 | 2006-01-01 | Telik Inc | Sulfonylethyl phosphorodiamidates |
| CA2569826C (en) | 2004-06-30 | 2013-07-16 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| AU2005269716B2 (en) | 2004-07-20 | 2011-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| WO2006031806A2 (en) | 2004-09-10 | 2006-03-23 | Atherogenics, Inc. | 2-thiopyrimidinones as therapeutic agents |
| WO2006078711A2 (en) | 2005-01-19 | 2006-07-27 | Mgi Gp, Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp |
| CN101142198B (zh) | 2005-02-17 | 2012-10-31 | 辛塔制药公司 | 用于治疗疾病的异*唑坎布雷它斯丁衍生物 |
| US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| US7638558B2 (en) | 2005-04-01 | 2009-12-29 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
| US20060229277A1 (en) | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| WO2006110683A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| US8242103B2 (en) | 2005-05-19 | 2012-08-14 | Merck Sharp & Dohme Limited | Sulphamides for treatment of cancer |
| ES2392544T3 (es) | 2005-06-07 | 2012-12-11 | Yale University | Métodos de tratamiento del cáncer y otras enfermedades o estados patológicos usando LFMAU y LDT |
| BRPI0612138B8 (pt) | 2005-06-15 | 2021-05-25 | Cardiome Pharma Corp | compostos éter aminocicloexílicos e método para fazer os mesmos |
| HRP20110804T1 (hr) | 2005-06-23 | 2011-11-30 | Merck Sharp & Dohme Corp. | Benzocikloheptapiridini kao inhibitori receptora tirozin kinaze met |
| PT3248613T (pt) | 2005-07-18 | 2022-03-16 | Seagen Inc | Conjugados de ligante de fármaco e beta-glucuronida |
| US7700773B2 (en) | 2005-09-09 | 2010-04-20 | Schering Corporation | 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors |
| US8378117B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| CA2626016A1 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| CN101316597B (zh) | 2005-11-03 | 2013-04-17 | 顶点医药品公司 | 用作激酶抑制剂的氨基嘧啶 |
| EP1948132B1 (en) | 2005-11-18 | 2009-08-05 | Synhton B.V. | Zolpidem tablets |
| CA2633500A1 (en) | 2005-12-20 | 2007-07-05 | President And Fellows Of Harvard College | Compounds, screens, and methods of treatment |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| US7910607B2 (en) * | 2006-03-10 | 2011-03-22 | The Trustees Of California State University | Nitroxide free radical synergized antineoplastic agents |
| EP2001400B1 (en) | 2006-03-14 | 2014-05-07 | Neuren Pharmaceuticals Limited | Oral formulations of glycyl-2-methylprolyl-glutamate |
| WO2007107545A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 |
| JP2009531364A (ja) | 2006-03-28 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | アミド誘導体およびｇタンパク質関連疾患の処置のためのそれらの使用 |
| CN101415409B (zh) | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| CA2649861A1 (en) | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
| GB0609378D0 (en) | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
| US8119652B2 (en) | 2006-05-18 | 2012-02-21 | Merck Sharp & Dohme Corp. | Aryl-fused spirocyclic compounds |
| US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
| EP2038262B1 (en) | 2006-05-25 | 2014-11-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| JP5284955B2 (ja) | 2006-06-20 | 2013-09-11 | アボット・ラボラトリーズ | Ｐａｒｐ阻害剤としてのピラゾロキナゾリノン |
| US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| US20080213249A1 (en) | 2006-07-07 | 2008-09-04 | The Scripps Research Insitute | Use of Retro-Aldol Reaction to Generate Reactive Vinyl Ketone for Attachment to Antibody Molecules by Michael Addition Reaction for Use in Immunostaining and Immunotargeting |
| TW200813021A (en) | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| WO2008009407A2 (en) | 2006-07-17 | 2008-01-24 | Novartis Ag | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| EP2049563B1 (en) | 2006-07-24 | 2014-03-12 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
| JP2010500370A (ja) | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| US7683060B2 (en) | 2006-08-07 | 2010-03-23 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| CA2659425C (en) | 2006-08-17 | 2017-06-20 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US20080085882A1 (en) * | 2006-08-18 | 2008-04-10 | University Of North Texas Health Science Center At Fort Worth | Compositions and Methods for Potentiation of Cancer Agents |
| ES2375284T3 (es) | 2006-08-23 | 2012-02-28 | Eisai R&D Management Co., Ltd. | Sal de un derivado de fenoxipiridina, o cristal de la misma, y procedimiento de producción de la misma. |
| RU2009110243A (ru) | 2006-08-23 | 2010-09-27 | Новартис АГ (CH) | Амиды как ингибиторы сфингомиелина |
| US7956064B2 (en) | 2006-09-01 | 2011-06-07 | Cylene Pharmaceuticals, Inc. | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators |
| WO2008030408A2 (en) | 2006-09-05 | 2008-03-13 | Yale University | Proteomimetic compounds as inhibitors of the interaction of a nuclear receptor with coactivator peptides |
| EP2526934B1 (en) | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| US8242080B2 (en) | 2006-10-13 | 2012-08-14 | The Regents Of The University Of California | Inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface |
| TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物 |
| US7842278B2 (en) | 2006-10-27 | 2010-11-30 | Natural Pharmacia International, Inc. | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof |
| CN101573345A (zh) | 2006-10-31 | 2009-11-04 | 先灵公司 | 作为蛋白激酶抑制剂的2-氨基噻唑-4-甲酰胺 |
| CA2667487C (en) | 2006-11-06 | 2017-04-04 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20120164075A1 (en) | 2006-11-21 | 2012-06-28 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of mammalian diseases |
| US20080125397A1 (en) | 2006-11-28 | 2008-05-29 | Telik, Inc. | 2 (SULFONYL)ETHYL N,N,N',N' tetrakis(2 chloroethyl)phosphorodia |
| US7655799B2 (en) | 2006-11-29 | 2010-02-02 | Telik, Inc. | 2{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates |
| WO2008079973A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Egfr binding peptides and uses thereof |
| US8834920B2 (en) | 2006-12-21 | 2014-09-16 | Alza Corporation | Liposome composition for targeting egfr receptor |
| US20080293648A1 (en) | 2007-01-05 | 2008-11-27 | Saha Pharmaceuticals, Inc. | Compositions and Methods for Cancer Treatment |
| US8470323B2 (en) | 2007-01-09 | 2013-06-25 | The Trustees Of The University Of Pennsylvania | Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display |
| US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
| CA2676145A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | 1-benzenesulfonyl-1h-indole derivatives as inhibitors of ccr9 activity |
| EP2491923A3 (en) | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| CA2677046A1 (en) | 2007-02-28 | 2008-09-04 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
| ES2381446T3 (es) | 2007-03-08 | 2012-05-28 | Janssen Pharmaceutica, N.V. | Derivado de quinolinona como inhibidores de PARP y TANK |
| CA2783589A1 (en) | 2007-03-09 | 2008-09-18 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| WO2008112277A2 (en) | 2007-03-13 | 2008-09-18 | Wake Forest University | Compositions and methods for treating cancer |
| US20100184706A1 (en) | 2007-03-20 | 2010-07-22 | Bachovchin William W | Fap-activated chemotherapeutic compounds, and methods of use thereof |
| ES2430614T3 (es) | 2007-04-10 | 2013-11-21 | Exelixis, Inc. | Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa |
| BRPI0810195A2 (pt) | 2007-04-13 | 2014-12-30 | Novartis Ag | Moduladores de gpbar1 |
| CN101663033B (zh) | 2007-04-18 | 2013-01-16 | 默沙东公司 | 作为smo拮抗剂的三唑衍生物 |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| AT505225A1 (de) | 2007-04-26 | 2008-11-15 | Sanochemia Pharmazeutika Ag | 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen |
| US7838495B2 (en) | 2007-04-27 | 2010-11-23 | University Of Maryland, Baltimore | Compositions and methods of use of EPB1, and ErbB3 binding protein |
| JP5389785B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
| AU2008254273B2 (en) | 2007-05-15 | 2013-03-28 | Otsuka Pharmaceutical Co., Ltd. | Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival |
| WO2008144506A1 (en) | 2007-05-16 | 2008-11-27 | University Of Maryland, Baltimore | Apoptotic pathway targeting for the diagnosis and treatment of cancer |
| US20110288023A1 (en) | 2007-06-08 | 2011-11-24 | The Regents Of The University Of California Office Of Technology Transfer | Cancer drug delivery using modified transferrin |
| WO2009003911A1 (en) | 2007-06-29 | 2009-01-08 | 4Sc Ag | Thiophene-imidazopyridines |
| JP2010532756A (ja) | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法 |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| KR20100053607A (ko) | 2007-08-03 | 2010-05-20 | 패시트 바이오테크 코포레이션 | 항-ｔｗｅａｋ 수용체 항체의 치료 용도 |
| ES2514517T3 (es) | 2007-08-10 | 2014-10-28 | Mitsubishi Tanabe Pharma Corporation | Nueva sal de compuesto de isoquinolina y cristal de la misma |
| HUE027443T2 (en) | 2007-09-10 | 2016-10-28 | Boston Biomedical Inc | A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors |
| SI2209375T1 (sl) | 2007-10-03 | 2014-12-31 | Eisai Inc. | Spojine inhibitorja PARP in metode uporabe |
| WO2009045504A1 (en) | 2007-10-04 | 2009-04-09 | President And Fellows Of Harvard College | Methods and compositions for treating cancer and modulating signal transduction and metabolism pathways |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| WO2009054941A1 (en) | 2007-10-25 | 2009-04-30 | Merck & Co., Inc. | Therapeutic compounds |
| CA2705509A1 (en) | 2007-11-14 | 2009-05-22 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-gpr49 antibody |
| US8268827B2 (en) | 2007-11-15 | 2012-09-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. | Pyridazinone derivatives as PARP inhibitors |
| US8088749B2 (en) | 2007-12-12 | 2012-01-03 | The Regents Of The University Of Michigan | Compositions and methods for treating cancer |
| WO2009082662A1 (en) | 2007-12-21 | 2009-07-02 | Novartis Ag | Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP2011511078A (ja) | 2008-02-06 | 2011-04-07 | レアド トヘラペウトイクス，インコーポレーテッド | ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤 |
| WO2009099677A2 (en) | 2008-02-08 | 2009-08-13 | Aileron Therapeutics, Inc. | Therapeutic peptidomimetic macrocycles |
| WO2009102707A2 (en) | 2008-02-11 | 2009-08-20 | Auspex Pharmaceuticals, Inc. | Substituted oxazaphosphorines |
| EP2259791A2 (en) | 2008-03-05 | 2010-12-15 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer |
| MX2010010012A (es) | 2008-03-11 | 2010-10-20 | Incyte Corp | Derivados de azetidina y ciclobutano como inhibidores de jak. |
| RU2506267C2 (ru) | 2008-03-31 | 2014-02-10 | Дженентек, Инк. | Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение |
| EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| CN102076717B (zh) | 2008-04-30 | 2016-02-03 | 伊缪诺金公司 | 交联剂和它们的用途 |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8207169B2 (en) | 2008-06-03 | 2012-06-26 | Msd K.K. | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D |
| GB2460672B (en) | 2008-06-04 | 2012-01-04 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents |
| EP2133334A1 (en) | 2008-06-09 | 2009-12-16 | DAC S.r.l. | Heterocyclic derivatives as HDAC inhibitors |
| US8207195B2 (en) | 2008-06-26 | 2012-06-26 | Inspire Pharmaceuticals, Inc. | Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds |
| SG192485A1 (en) | 2008-07-08 | 2013-08-30 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| CA2730377C (en) | 2008-07-11 | 2017-09-19 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
| EP2307413B1 (en) | 2008-07-15 | 2015-09-09 | F. Hoffmann-La Roche AG | Novel phenyl-imidazopyridines and pyridazines |
| MX2011000661A (es) | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
| US8217076B2 (en) | 2008-07-17 | 2012-07-10 | Colorado State University Research Foundation | Method for preparing largazole analogs and uses thereof |
| US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| WO2010021822A2 (en) | 2008-07-30 | 2010-02-25 | The Regents Of The University Of California | Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites |
| WO2010014913A1 (en) | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| EP2326650B9 (en) | 2008-08-06 | 2014-09-10 | BioMarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| NZ591113A (en) | 2008-08-26 | 2012-07-27 | Boehringer Ingelheim Int | Thienopyrimidine linked to phenyl or pyridine via an nh amine for pharmaceutical compositions |
| US20100068302A1 (en) | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| CN102177140B (zh) | 2008-10-08 | 2016-01-27 | 赛福伦公司 | 用于制备苯达莫司汀的方法 |
| US20100111901A1 (en) | 2008-11-03 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Triazole inhibitors of aromatase |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
| WO2010068920A2 (en) | 2008-12-12 | 2010-06-17 | Auspex Pharmaceutical, Inc. | Diaminoquinazoline inhibitors of dihydrofolate reductase |
| WO2010080570A2 (en) | 2008-12-18 | 2010-07-15 | New York University | Tumor therapy with antitumor agents in combination with sindbis virus-based vectors |
| US20100173013A1 (en) | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
| BRPI1007358A2 (pt) | 2009-01-23 | 2018-03-06 | Takeda Pharmaceutical Company Limited | inibidores de poli (adp-ribose) polimerase (parp) |
| HRP20151325T1 (hr) | 2009-01-23 | 2016-01-01 | Rigel Pharmaceuticals, Inc. | Pripravci i postupci za inhibiciju jak puta |
| CN104523661A (zh) | 2009-02-06 | 2015-04-22 | 南加利福尼亚大学 | 含有单萜的治疗组合物 |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| RU2011141123A (ru) | 2009-03-11 | 2013-04-20 | Плексксикон, Инк. | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RAF-КИНАЗ |
| EP2413901A4 (en) | 2009-03-30 | 2015-05-06 | Cerulean Pharma Inc | POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES |
| WO2010114805A1 (en) | 2009-03-31 | 2010-10-07 | The Trustees Of The University Of Pennsylvania | Methods of treating cancer with phenformin |
| US8680139B2 (en) | 2009-04-01 | 2014-03-25 | Progenra | Anti-neoplastic compounds, compositions and methods |
| EP2417123A2 (en) | 2009-04-06 | 2012-02-15 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US20100291025A1 (en) | 2009-04-13 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | Indazole inhibitors of tyrosine kinase |
| SG175287A1 (en) | 2009-04-24 | 2011-11-28 | Hoffmann La Roche | Inhibitors of bruton's tyrosine kinase |
| US20110053968A1 (en) | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| US9151762B2 (en) | 2009-06-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Identification of DSG-3 as a biomarker for the detection of metastasis in lymph nodes |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| US8232318B2 (en) | 2009-07-31 | 2012-07-31 | The General Hospital Corporation | Approaches to treat cancer using HB-EGF inhibitors |
| MY161541A (en) * | 2009-07-31 | 2017-04-28 | Shin Maeda | Cancer metastasis inhibitor |
| EP2470546B1 (en) | 2009-08-28 | 2013-07-24 | Takeda Pharmaceutical Company Limited | Hexahydrooxazinopteridine compounds for use as mtor inhibitors |
| CN102625803A (zh) | 2009-09-11 | 2012-08-01 | 赛林药物股份有限公司 | 药学上有用的杂环-取代的内酰胺 |
| BR112012005970A2 (pt) | 2009-09-16 | 2015-09-08 | Cylene Pharmaceuticals Inc | moduladores tricíclicos de proteína quinase |
| ES2444779T3 (es) | 2009-09-28 | 2014-02-26 | F. Hoffmann-La Roche Ag | Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| WO2011050242A1 (en) | 2009-10-23 | 2011-04-28 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
| EP2501412B1 (en) | 2009-11-18 | 2017-03-29 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
| JP5802676B2 (ja) | 2009-12-04 | 2015-10-28 | センワ バイオサイエンシズ インコーポレイテッド | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
| US20110195066A1 (en) | 2010-02-05 | 2011-08-11 | Auspex Pharmaceuticals, Inc. | Quinoline inhibitors of tyrosine kinase |
| CA3162668A1 (en) | 2010-02-12 | 2011-08-18 | Gentelon, Inc. | Compositions and methods for treating depression |
| US20110206661A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Trimethoxyphenyl inhibitors of tyrosine kinase |
| AR080328A1 (es) | 2010-02-26 | 2012-03-28 | Boehringer Ingelheim Int | Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros |
| UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| AU2011243947A1 (en) | 2010-04-23 | 2012-12-06 | Piramal Enterprises Limited | Nitric oxide releasing prodrugs of therapeutic agents |
| WO2011143422A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| WO2011150073A2 (en) | 2010-05-26 | 2011-12-01 | Shriners Hospitals For Children | Compositions comprising the nc2 domain of collagen ix and methods of using same |
| NZ604040A (en) | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| WO2012047339A2 (en) | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| EP2605650A4 (en) * | 2010-08-18 | 2014-05-21 | Del Mar Pharmaceuticals | COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYL DIANHYDROGALACTITOL |
| WO2012044832A1 (en) | 2010-09-30 | 2012-04-05 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
| US8846623B2 (en) | 2010-10-25 | 2014-09-30 | Academia Sinica | Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| SI2786753T1 (sl) | 2010-11-12 | 2019-05-31 | Pharma Mar S.A. | Kombinacijska terapija s protitumorskim antibiotikom |
| US20140088021A1 (en) | 2011-05-27 | 2014-03-27 | Nektar Therapeutics | Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds |
| US8637490B2 (en) | 2011-07-01 | 2014-01-28 | Uwm Research Foundation, Inc. | Anti-cancer agents |
| EP2734228A4 (en) | 2011-07-18 | 2015-04-08 | Ohio State Innovation Foundation | FTY720 INCREASES CD74 RECEPTOR EXPRESSION AND SENSITIZES CANCER CELLS TO CELL DEATH INDUCED BY ANTI-CD74 ANTIBODIES |
| CN110711188A (zh) * | 2012-01-20 | 2020-01-21 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
| KR101374820B1 (ko) | 2012-01-30 | 2014-03-17 | 광주과학기술원 | 페오포르바이드-α 컨쥬게이트 및 그의 용도 |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| EA201492082A1 (ru) | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| US20140005148A1 (en) | 2012-06-29 | 2014-01-02 | Coldstream Laboratories Inc. | Stable liquid formulations of nitrogen mustards |
-
2014
- 2014-04-08 JP JP2016507620A patent/JP2016519684A/ja active Pending
- 2014-04-08 US US14/783,137 patent/US11491154B2/en active Active
- 2014-04-08 KR KR1020157032123A patent/KR20160061911A/ko not_active Ceased
- 2014-04-08 EP EP14782363.7A patent/EP2983674A4/en not_active Ceased
- 2014-04-08 CN CN201480032586.8A patent/CN105492011A/zh active Pending
- 2014-04-08 WO PCT/US2014/033391 patent/WO2014168986A1/en not_active Ceased
- 2014-04-08 AU AU2014251038A patent/AU2014251038A1/en not_active Abandoned
-
2019
- 2019-05-28 JP JP2019099028A patent/JP2019135268A/ja active Pending
- 2019-10-01 AU AU2019240599A patent/AU2019240599A1/en not_active Abandoned
-
2021
- 2021-10-27 AU AU2021257978A patent/AU2021257978A1/en not_active Abandoned
-
2022
- 2022-11-07 US US17/982,233 patent/US12336993B2/en active Active
-
2024
- 2024-02-02 AU AU2024200650A patent/AU2024200650A1/en not_active Abandoned
-
2025
- 2025-06-19 US US19/243,604 patent/US20250312347A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519684A5 (enExample) | ||
| US12336993B2 (en) | Therapeutic benefit of suboptimally administered chemical compounds | |
| US20230092181A1 (en) | Intermittent dosing of mdm2 inhibitor | |
| JP2013537552A5 (ja) | ジアンヒドロガラクチトール及びジアセチルジアンヒドロガラクチトール等の置換ヘキシトールを含む準最適に投与された化合物の治療的有効性を改良するための組成物及び置換ヘキシトールを含む薬剤を調製するための方法 | |
| JP2022088616A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
| JP2021004244A (ja) | 多形神経膠芽腫及び髄芽腫を含む新生物疾患及び癌幹細胞を処置するためのジアンヒドロガラクチトール及び類似体を含めた置換ヘキシトールの使用 | |
| JP2016520622A5 (enExample) | ||
| JP6890659B2 (ja) | ＨＤＭ２−ｐ５３相互作用阻害剤の用量およびレジメン | |
| CN112472699A (zh) | 改善比生群及衍生物的治疗益处的组合方法 | |
| TW200418837A (en) | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | |
| JP2020183445A (ja) | 医薬組成物 | |
| US20190091195A1 (en) | Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer | |
| JP2024542248A (ja) | Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法 | |
| US20160151406A1 (en) | Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides | |
| CA3235940A1 (en) | Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections | |
| US8293764B2 (en) | Compositions and methods for disruption of BRCA2-Rad51 interaction | |
| US20240156808A1 (en) | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | |
| NL2020004B1 (en) | Treatment of diffuse intrinsic pontine glioma | |
| US20200306254A1 (en) | Combination of erk1/2 inhibitor compound with gemcitabine or with gemcitabine and nab-paclitaxel for use in treatment of pancreatic cancer | |
| HK1224581A1 (en) | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor |